For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
News Release
Rescheduling marijuana to a less restrictive category will benefit liberty and public health
President Trump signed an executive order today intended to fast track the rescheduling of cannabis from a Schedule I substance, the same as heroin,…
News Release
CEI Study: Government laws against pharmacy ownership would increase costs, restrict access for consumers
Innovation is reshaping how Americans get their prescription medications. Whether picking up medications in person, ordering online, or getting same-day delivery from services like Capsule,…
Study
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs, rapid…
Search Posts
Letters
Coalition Letter to End IRA Prescription Drug Price Controls
October 31, 2023 Dear Members of Congress, When the Inflation Reduction Act was passed and signed into law a year ago, the legislation granted the…
Blog
This week in ridiculous regulations: Blood donations to mortality tables
Poland voted its nationalist-populist government out of power. The US House of Representatives remained without a speaker, but with a lot of drama. Agencies issued…
City Journal
Equity vs. Evidence
The U.S. Preventive Services Task Force—a volunteer panel of national experts in prevention and evidence-based medicine that makes recommendations for clinical preventive services such as…
National Review
Restricting Pharmacy Benefit Managers Could Decrease Competition and Increase Drug Costs
Congress is considering multiple bills that aim to restrict the ability of pharmacy benefit managers (PBMs) to negotiate discounts and rebates and to require the PBMs…
PCMA
Just the Facts: Research and Analysis Finds Anti-PBM Legislation Does Not Lower Prescription Drug Costs for Patients
PCMA cites CEI’s Joel Zinberg anti PBM legislation: “This policy would significantly change drug pricing and utilization and shift billions of dollars annually from patients…
Wall Street Journal
Court to FDA: Stop Playing Doctor
The Food and Drug Administration regulates pharmaceuticals, but it has no business playing doctor and giving you medical advice. That’s the message of a Sept.
